ArticleClinics (Sao Paulo, Brazil)2026

Systematic review of the efficacy and safety of lenvatinib vs. sorafenib as first-line treatments for hepatocellular carcinoma.

Wentao Bo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.